Glucagen Hypokit

Glucagen Hypokit is a ready‑to‑use injectable solution that contains the hormone glucagon as its active ingredient. It is supplied in a pre‑filled hypodermic kit for intramuscular, intravenous, or subcutaneous administration. Marketed in the European Union as a prescription‑only product, Glucagen Hypokit is used to rapidly raise blood glucose levels in patients experiencing severe hypoglycemia. The kit includes a syringe, needle, and diluent, allowing professionals to deliver a dose in settings.

Glucagen Hypokit is indicated for the treatment of severe hypoglycemia when rapid glucose elevation is required.

- Emergency reversal of hypoglycemia in patients with insulin‑induced low blood glucose. - Use in individuals with diabetes who are unconscious or unable to ingest carbohydrates. - Administration when oral glucose therapy is ineffective or impractical. - Management of hypoglycemic episodes in hospital or pre‑hospital settings. - Use in pediatric patients with congenital hyperinsulinism when other therapies fail. - Administration by trained personnel during ambulance transport for acute hypoglycemic events.

Glucagen Hypokit may cause a range of adverse reactions, most of which are mild and transient.

Common: - Nausea or vomiting, typically occurring shortly after injection - Flushing or a sensation of warmth, usually transient - Headache or dizziness, often mild and resolves quickly - Transient increase in blood pressure, generally not clinically significant

Serious: - Allergic reactions such as rash, itching, swelling, or hives that may require medical attention - Severe hypoglycemia recurrence if the administered dose does not adequately raise glucose levels - Cardiovascular events such as arrhythmia or chest pain, particularly in patients with pre‑existing heart disease - Pancreatitis signs including abdominal pain and elevated enzymes, though rare

When using Glucagen Hypokit, certain precautions should be observed to ensure safe and effective administration.

- Confirm severe hypoglycemia diagnosis before administration; glucagon is not indicated for mild low glucose. - Avoid intramuscular injection into the gluteal region to reduce risk of nerve injury. - Do not reuse the pre‑filled kit; discard after a single use. - Monitor blood glucose levels after injection to assess response and need for additional treatment. - Exercise caution in patients with pheochromocytoma or insulinoma, as glucagon may exacerbate symptoms. - Store the kit at controlled room temperature, protecting it from light and moisture.

Glucagen Hypokit can interact with certain medications or substances, influencing its effectiveness or safety profile.

Avoid: - Concurrent use of beta‑blockers, which may mask typical glucagon‑induced tachycardia and affect glucose response. - Administration together with other hyperglycemic agents that could cause excessive blood glucose elevation. - Concurrent use of somatostatin analogues, which can inhibit glucagon’s action and reduce efficacy.

Use with caution: - Patients receiving oral anticoagulants, as glucagon may alter platelet function. - Individuals on monoamine oxidase inhibitors, due to potential cardiovascular effects. - Pregnant or breastfeeding women, because safety data are limited. - Patients with cardiovascular disease, as glucagon may increase heart rate and myocardial oxygen demand.